Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jazz Pharmaceuticals PLC

99.90
-1.5400-1.52%
Volume:879.72K
Turnover:87.21M
Market Cap:6.07B
PE:13.31
High:104.06
Open:101.58
Low:97.51
Close:101.44
Loading ...

Jazz Pharmaceuticals Q4 Non-GAAP Earnings, Revenue Rise; 2025 Guidance Issued

MT Newswires Live
·
26 Feb

Jazz: Q4 Earnings Snapshot

Associated Press Finance
·
26 Feb

Jazz Pharmaceuticals Plc Outlook 2025 Adj Net Income per Diluted Share $22.50 - $24.00

THOMSON REUTERS
·
26 Feb

Jazz Pharmaceuticals Q4 2024 Adj. EPS $6.60 Beats $5.81 Estimate, Sales $1.088B Beat $1.060B Estimate

Benzinga
·
26 Feb

BRIEF-Jazz Pharmaceuticals Q4 Adjusted EPS USD 6.6 Vs. IBES Estimate USD 5.81

Reuters
·
26 Feb

Jazz Pharmaceuticals Q4 EPS USD 3.11

THOMSON REUTERS
·
26 Feb

Jazz Pharmaceuticals Plc: 2025 Total Revenue Guidance of $4.15 - $4.40 Bln

THOMSON REUTERS
·
26 Feb

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance

THOMSON REUTERS
·
26 Feb

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance

PR Newswire
·
26 Feb

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioCryst (BCRX), Addus Homecare (ADUS) and Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
25 Feb

Barclays Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
25 Feb

Top Calls on Wall Street: Nvidia, Netflix, Coinbase, Eli Lilly, Reddit, CVS, Broadcom, Dell, Walmart & More

Tiger Newspress
·
14 Feb

Wells Fargo Upgrades Jazz Pharmaceuticals to Overweight From Equalweight, Adjusts Price Target to $170 From $130

MT Newswires Live
·
13 Feb

Jazz Pharmaceuticals Raised to Overweight From Equal-Weight by Wells Fargo

Dow Jones
·
13 Feb

Jazz (JAZZ) Surges 5.2%: Is This an Indication of Further Gains?

Zacks
·
12 Feb

Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025

PR Newswire
·
12 Feb

Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again

Zacks
·
06 Feb

Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises

Zacks
·
31 Jan

BRIEF-Jazz Pharmaceuticals Expects To Meet 2024 Revenue Guidance

Reuters
·
13 Jan

Jazz Pharmaceuticals Plc - Expects to Meet 2024 Revenue Guidance

THOMSON REUTERS
·
13 Jan